Navigation Links
Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO

stration trials and has the potential to be the first Hsp90 inhibitor to reach the market. Our TIME registration program for tanespimycin in patients with multiple myeloma is on track to be initiated in the third quarter of 2007, which will be a major milestone for our company."

Phase 2 Tanespimycin Melanoma Trial

Tanespimycin binds to and inhibits the activity of Hsp90. Hsp90 inhibition results in the degradation of a variety of RAF family proteins, including mutant BRAF. As the majority of melanomas have activation of the BRAF-MAP kinase pathway, it is postulated that tanespimycin interrupts the MAP kinase pathway and may lead to clinically significant anti-melanoma effects. The Phase 2 trial of tanespimycin was designed as a multi-center two-stage Simon design study; continuation to the second stage required at least 1 of the first 9 patients to have a progression-free survival (PFS) time of at least 24 weeks, the primary endpoint of the trial. Eligible patients had stage M1 melanoma, measurable/unresectable disease and had progressed within 3 months of study entry with no more than 1 prior chemotherapy treatment for metastatic melanoma. Tanespimycin was administered at a dose of 275 mg/m2 by 1-2 hour intravenous infusion 2 times per week every 2 out of 3 weeks until disease progression or toxicity. 20 patients have been enrolled, and efficacy data are available on 14 evaluable patients. One of the 6 evaluable patients with a BRAF mutation (V600E) showed evidence of anti-melanoma activity. An additional patient with BRAF mutation continues on study but is too early to assess for efficacy at present. The safety profile has been manageable and included predominantly Grade 1 and 2 toxicities (constitutional and gastrointestinal symptoms). Grade 3 or 4 toxicity, which was generally manageable and reversible, resulted in treatment discontinuation in 2 patients. Accrual is continuing toward the goal of enrolling a total of 30 evaluable patients (with cont
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:7/30/2015)... July 30, 2015 PTC Therapeutics, Inc. (NASDAQ: ... reported financial results for the second quarter ending June ... many fronts across the organization.  We are excited to ... dystrophy clinical trial ever conducted with topline results expected ... Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is now ...
(Date:7/30/2015)... July 30, 2015  Cleveland Clinic President Wael ... address last month that industry is compelled to adopt ... gain the efficiencies—and develop the transformational innovations -- required ... comments were preceded by Doug Kohrs , past ... moderator, who stressed that industry must add "episode of ...
(Date:7/30/2015)... VALLEY COTTAGE, New York , July 30, 2015 ... the release of its latest report titled, "Continuous Glucose ... 2015 - 2020". According to the report, the global ... 402.0 Mn in 2014 and is expected to reach ... 12.1% during the forecast period, 2015 to 2020. ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4
... N.Y., June 23 A landmark study has ... failure or death in patients with heart disease ... with defibrillator (CRT-D) versus patients who received only ... , MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with ...
... LAUSANNE, Switzerland, June 23 Debiopharm Group,(Debiopharm), a ... the development of prescription drugs that target unmet medical,needs, ... Moapar(R),and Salvapar(R)), was launched in Germany in May 2009, ... also launched on a preliminary basis in,Belgium. The effective ...
Cached Medicine Technology:New Therapy Found to Prevent Heart Failure 2Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries 2
(Date:7/30/2015)... , ... July 30, 2015 , ... In a meaningful ... at Serenity Palms Drug Addiction Treatment Center have created an addiction graveyard. Sharing this ... of its most beloved residents, Rocky Hudson . Hudson (1945-2015) fell in love ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Telemedicine ... Meeting and Tradeshow focused exclusively on telemedicine, telehealth and mHealth. The meeting, expected ... vendors, will take place May 14-17, 2016 in Minneapolis, MN. , ATA’s annual ...
(Date:7/30/2015)... ... July 30, 2015 , ... " ... which takes a look at small, medium, and large businesses making an impact ... conducted the business review and shared with viewers how DevExpress has provided software ...
(Date:7/30/2015)... , ... July 30, 2015 ... ... a video, “Beachside Nursing Center,” to announce its position as one of ... Beachside's administrator and staff members support the CMS rating system, which monitors ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... company and UCLA’s Jonsson Comprehensive Cancer Center (JCCC) mutually agreed to ... new collaboration, OncLive’s editorial and marketing groups will help spread the news about ...
Breaking Medicine News(10 mins):Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:Beachside Nursing Center Releases New Video 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4
... account , TUESDAY, Sept. 1 (HealthDay News) -- Many hospitals ... Report list of best hospitals for heart disease but ... say. , "If you really want to know how a ... readmission, you should look directly at government statistics for those ...
... flu strains , TUESDAY, Sept. 1 (HealthDay News) -- Fears ... this year may be unfounded, say researchers at the University ... the swine flu pandemic did not take a virulent turn ... did spread more rapidly than the other viruses, confirming the ...
... , PISCATAWAY, N.J., Sept. 1 ... in advanced injection technologies, today announced that Leslie Bernhard, an ... Leonard Osser who had previously led the Company as Chairman ... interim Chief Executive Officer since February 2009 and was formerly ...
... Ind., Sept. 1 Zimmer Holdings, Inc. (NYSE: ZMH ; SWX: ... the month of September: , , , ... 2009, at 11:30 a.m. Eastern Time; , Morgan Stanley ... 8:35 a.m. Eastern Time; and , UBS Global Life ...
... , CARDIFF, Calif., Sept. 1 ... http://www.jedimindinc.com ) announced today that their Medical Division ... patients in wheelchairs. An estimated 1.6 million Americans residing outside ... Health Interview Survey on Disability (NHIS-D). Jedi Mind,s Medical Division ...
... ... Drug Development, Regulatory Approval, and Access to Patients from October 15-16, 2009 in Toronto, ... ... will host Personalized Medicine: Biomarkers and Diagnostics in Drug Development, Regulatory Approval, and ...
Cached Medicine News:Health News:Government Best Source for U.S. Hospital Data, Study Finds 2Health News:Swine Flu May Be Less Dangerous Than Predicted: Study 2Health News:Swine Flu May Be Less Dangerous Than Predicted: Study 3Health News:Milestone Scientific Announces Key Leadership Changes 2Health News:Milestone Scientific Announces Key Leadership Changes 3Health News:Jedi Mind Medical Applications Division to Concentrate on Wheelchair Mobility Applications 2Health News:DIA Conference to Explore The Science and Scope of Personalized Medicine 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: